Related Experiment Videos
Somatostatin receptor imaging of endocrine gastrointestinal tumors
E P Krenning1, D J Kwekkeboom, H Y Oei
1Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Unlabelled:
Somatostatin receptors are present on various tumors of neuroendocrine origin. We recently developed a technique for the in vivo visualization of somatostatin receptor positive tumors, which offers a powerful alternative to tumor imaging with labeled monoclonal antibodies. Instead of injecting radiolabeled antibodies against the somatostatin receptor, we labeled a somatostatin analogue ([Tyr3]-octreotide) which is known to bind specifically to the somatostatin receptor, and injected this labeled hormone analogue in order to visualize somatostatin receptor positive tumors. We previously reported the successful visualization of the primary tumors or metastases of various endocrine gastrointestinal tumors after injection of the iodinated somatostatin analogue [123I-Tyr3]-octreotide. The primary tumors or metastases of 12 out of 13 carcinoids, 3 out of 3 gastrinomas, 2 out of 4 insulinomas, and 1 out of 1 somatostatinoma were visualized. Using 111In-coupled octreotide, we were able to visualize 19 out of 19 carcinoids, 7 out of 7 gastrinomas, 4 out of 7 insulinomas, 1 out of 1 glucagonoma, and 3 out of 3 non-functioning endocrine pancreatic tumors, but none of 18 exocrine pancreatic tumors. In a large proportion of patients with endocrine gastrointestinal tumors, previously unrecognized metastases were demonstrated. Also, the absence or presence of in vivo visualization of these tumors after the injection of radiolabeled octreotide seems to predict the ability of octreotide therapy to control symptoms caused by hormonal secretion from these tumors.
In Conclusion:
111In-octreotide scintigraphy is a simple and sensitive technique for localizing of the primary tumor and its metastases in the majority of patients with carcinoids or endocrine pancreatic tumors.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Radiolabeled somatostatin analogues like [111In]-octreotide effectively visualize neuroendocrine tumors and their metastases. This imaging technique aids in diagnosis and may predict treatment response to octreotide therapy.
Area of Science:
- Nuclear medicine
- Oncology
- Endocrinology
Background:
- Somatostatin receptors are expressed on various neuroendocrine tumors.
- In vivo visualization of these tumors is crucial for diagnosis and management.
- Labeled monoclonal antibodies are one imaging approach, but hormone analogues offer an alternative.
Purpose of the Study:
- To evaluate the efficacy of a labeled somatostatin analogue, [Tyr3]-octreotide, for in vivo visualization of somatostatin receptor-positive tumors.
- To compare the diagnostic performance of [123I-Tyr3]-octreotide and [111In]-octreotide in various neuroendocrine tumors.
- To assess the potential of this imaging technique to detect previously unrecognized metastases and predict therapeutic response.
Main Methods:
- Development of a technique using a radiolabeled somatostatin analogue ([Tyr3]-octreotide) for tumor imaging.
- Administration of iodinated [123I-Tyr3]-octreotide and indium-111 coupled octreotide ([111In]-octreotide) to patients with suspected neuroendocrine tumors.
- Scintigraphic imaging to visualize primary tumors and metastases.
Main Results:
- [123I-Tyr3]-octreotide visualized most carcinoids, gastrinomas, and insulinomas.
- [111In]-octreotide demonstrated high sensitivity for carcinoids (19/19), gastrinomas (7/7), and endocrine pancreatic tumors (3/3), including non-functioning types.
- Previously unrecognized metastases were identified in a significant proportion of patients, and imaging results correlated with octreotide therapy effectiveness.
Conclusions:
- [111In]-octreotide scintigraphy is a simple, sensitive method for localizing primary neuroendocrine tumors and metastases.
- The technique is particularly effective for carcinoids and endocrine pancreatic tumors.
- In vivo visualization may predict the success of octreotide therapy in controlling tumor-related symptoms.